A prospective cohort study of the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland.
Adult
Aged
Aged, 80 and over
Breast Carcinoma In Situ
/ pathology
Breast Neoplasms
/ pathology
COVID-19
/ epidemiology
Carcinoma, Ductal, Breast
/ pathology
Carcinoma, Intraductal, Noninfiltrating
/ pathology
Carcinoma, Lobular
/ pathology
Cohort Studies
Cross Infection
/ epidemiology
Female
Humans
Male
Mastectomy
/ methods
Mastectomy, Segmental
/ methods
Middle Aged
Neoplasm Staging
Postoperative Complications
/ epidemiology
Prospective Studies
SARS-CoV-2
Scotland
/ epidemiology
State Medicine
Tumor Burden
Breast cancer
Breast conservation therapy
Breast surgery
COVID-19
Mammaplasty
Pandemics
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
16
06
2020
revised:
18
11
2020
accepted:
23
11
2020
pubmed:
8
12
2020
medline:
12
2
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
In order to minimise the risk of breast cancer patients for COVID-19 infection related morbidity and mortality prioritisation of care has utmost importance since the onset of the pandemic. However, COVID-19 related risk in patients undergoing breast cancer surgery has not been studied yet. We evaluated the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland region. A prospective cohort study of patients having breast cancer surgery was carried out in a geographical region during the first eight weeks of the hospital lockdown and outcomes were compared to the regional cancer registry data of pre-COVID-19 patients of the same units (n = 1415). 188 operations were carried out in 179 patients. Tumour size was significantly larger in patients undergoing surgery during hospital lockdown than before (cT3-4: 16.8% vs. 7.4%; p < 0.001; pT2 - pT4: 45.5% vs. 35.6%; p = 0.002). ER negative and HER-2 positive rate was significantly higher during lockdown (ER negative: 41.3% vs. 17%, p < 0.001; HER-2 positive: 23.4% vs. 14.8%; p = 0.004). While breast conservation rate was lower during lockdown (58.6% vs. 65%; p < 0.001), level II oncoplastic conservation was significantly higher in order to reduce mastectomy rate (22.8% vs. 5.6%; p < 0.001). No immediate reconstruction was offered during lockdown. 51.2% had co-morbidity, and 7.8% developed postoperative complications in lockdown. There was no peri-operative COVID-19 infection related morbidity or mortality. breast cancer can be safely provided during COVID-19 pandemic in selected patients.
Identifiants
pubmed: 33285400
pii: S0960-9776(20)30221-6
doi: 10.1016/j.breast.2020.11.015
pmc: PMC7687359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.